The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Production of functional chimaeric mouse/human antibody
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, M. H. (1959) · Interscience Publishers eBooks · doi:10.5962/bhl.title.6966 · Cited by 2,097
Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion
Köhler, G., & Milstein, C. (1976) · European Journal of Immunology · doi:10.1002/eji.1830060713 · Cited by 1,922
A better cell line for making hybridomas secreting specific antibodies
SHULMAN, M., WILDE, C. D., & KÖHLER, G. (1978) · Nature · doi:10.1038/276269a0 · Cited by 1,605
Self-citationTransformation of mammalian cells with genes from procaryotes and eucaryotes
Wigler, M., Sweet, R., Sim, G. K., Wold, B., Pellicer, A., Lacy, E., Maniatis, T., Silverstein, S., & Axel, R. (1979) · Cell · doi:10.1016/0092-8674(79)90093-x · Cited by 1,408
Methods in Immunology and Immunochemistry
(1967) · Elsevier eBooks · doi:10.1016/b978-0-12-754401-4.x5001-5 · Cited by 1,133
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Three-Dimensional Structure of Immunoglobulins
Amzel, L. M., & Poljak, R. J. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.004525 · Cited by 692
Hieter, P. A., Max, E. E., Seidman, J. G., Maizel, J. V., & Leder, P. (1980) · Cell · doi:10.1016/0092-8674(80)90168-3 · Cited by 393
The roles of individual polyoma virus early proteins in oncogenic transformation
Rassoulzadegan, M., Cowie, A., Carr, A., Glaichenhaus, N., Kamen, R., & Cuzin, F. (1982) · Nature · doi:10.1038/300713a0 · Cited by 350
Direct transfer of cloned genes from bacteria to mammalian cells.
Schaffner, W. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.4.2163 · Cited by 277
Cited by
Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics
Jayasena, S. D. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.9.1628 · Cited by 2,144
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
Orlandi, R., Güssow, D. H., Jones, P. T., & Winter, G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 706
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703
A humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., & Neuberger, M. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1351 · Cited by 607
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 550
Cancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 537
Monoclonal antibody therapeutics: history and future
Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 434
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
Reshaping Human Antibodies: Grafting an Antilysozyme Activity
Verhoeyen, M., Milstein, C., & Winter, G. (1988) · Science · doi:10.1126/science.2451287 · Cited by 345
Antibody‐Conjugated Nanoparticles for Biomedical Applications
Arruebo, M., Valladares, M., & González-Fernández, Á. (2009) · Journal of Nanomaterials · doi:10.1155/2009/439389 · Cited by 331
Bindon, C. I., Hale, G., Brüggemann, M., & Waldmann, H. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.1.127 · Cited by 292
A hapten-specific chimaeric IgE antibody with human physiological effector function
Neuberger, M. S., Williams, G. T., Mitchell, E. B., Jouhal, S. S., Flanagan, J. G., & Rabbitts, T. H. (1985) · Nature · doi:10.1038/314268a0 · Cited by 289
Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
Verma, R., Boleti, E., & George, A. J. T. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00077-5 · Cited by 265
Molecular imaging with nanoparticles: giant roles for dwarf actors
Debbage, P., & Jaschke, W. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0511-y · Cited by 264
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies
Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198
Fully human therapeutic monoclonal antibodies.
Weiner, L. M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192105.24583.83 · Cited by 164
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria
Robinson, M.-P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T. J., Tuckey, C., Riggs, P. D., Colussi, P. A., Noren, C. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9072 · Cited by 131
Analyzing the ‘Degree of Humanness’ of antibody sequences
Abhinandan, K. R., & Martin, A. C. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.100 · Cited by 99
Li, T., Pantazes, R. J., & Maranas, C. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105954 · Cited by 79
Herceptin: From the Bench to the Clinic
Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R. (2001) · Cancer Investigation · doi:10.1081/cnv-100000074 · Cited by 43
Metadata
- Authors
- Boulianne, G. L., Hozumi, N., & Shulman, M. J.
- Venue
- Nature
- Published
- 1984-12
- Volume
- 312
- Issue
- 5995
- Pages
- 643-646
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014099862
- Cited by
- 550
- References
- 17
- FWCI
- 18.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.